Design considerations on the proof of efficacy of functional foods

International Journal of Food Sciences and Nutrition

Volumn 63, Issue SUPPL. 1, 2012, Pages 43-50

  Baldi, Ileana ^a   Gregori, Dario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Power; Random effect; Sample size

Indexed keywords

ARTICLE; BIOASSAY; DIET SUPPLEMENTATION; EVIDENCE BASED PRACTICE; FOOD HANDLING; FOOD PACKAGING; FUNCTIONAL FOOD; HEALTH PROMOTION; HUMAN; MEDICAL RESEARCH; METHODOLOGY; NUTRITIONAL SCIENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BIOMEDICAL RESEARCH; ENDPOINT DETERMINATION; EVIDENCE-BASED PRACTICE; FOOD LABELING; FOOD TECHNOLOGY; FOOD, FORTIFIED; FUNCTIONAL FOOD; HEALTH PROMOTION; HUMANS; NUTRITIONAL SCIENCES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84857858330     PISSN: 09637486     EISSN: 14653478     Source Type: Journal    
DOI: 10.3109/09637486.2011.619967     Document Type: Article

References (29)

1. AbuMweis SS, Jew S, Jones PJ. 2010. Optimizing clinical trial design for assessing the efficacy of functional foods. Nutr Rev 68(8): 485-499
2. Altman DG, Royston P. 2000. What do we mean by validating a prognostic model? Stat Med 19(4):453-473 (Pubitemid 30126878)
3. Arai S, Yasuoka A, Abe K. 2008. Functional food science and food for specified health use policy in Japan: state of the art. Curr Opin Lipidol 19(1):69-73
4. Bagchi D, editor. 2008. Neutraceutical and functional food regulations. New York: Elsevier.
5. Blumberg J, Heaney RP, Huncharek M, Scholl T, Stampfer M, Vieth R. 2010. Evidence-based criteria in the nutritional context. Nutr Rev 68(8):478-484
6. Burzykowski T, Molenberghs G, Buyse M, editors. 2005. The evaluation of surrogate endpoint. New York: Springer.
7. Buyse M. 2009. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J 15(5): 421-425
8. Buyse M, Molenberghs G. 1998. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54(3):1014-1029 (Pubitemid 28429294)
9. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. 2010. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 7(6):309-317
10. Chow SC, Lu Q, Tse K. 2007. Statistical analysis for two-stage seamless design with different study endpoints. J Biopharm Stat 17(6):1163-1176 (Pubitemid 350135844)
11. Freedman LS, Graubard BI, Schatzkin A. 1992. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11(2):167-178
12. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. 1995. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 91(8):2274-2282
13. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD, 1998. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97(10):946-952 (Pubitemid 28125465)
14. Gould AL, Davies GM, Alemao E, Yin DD, Cook JR. 2007. Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther 29(5):778-794 (Pubitemid 47225184)
15. Heaney RP. 2006. Nutrition, chronic disease, and the problem of proof. Am J Clin Nutr 84(3):471-472 (Pubitemid 44713393)
16. Jew S, Vanstone CA, Antoine JM, Jones PJ. 2008. Generic and product-specific health claim processes for functional foods across global jurisdictions. J Nutr 138(6):1228S-1236S. (Pubitemid 351769156)
17. Lassere MN. 2008. The biomarker-surrogacy evaluation schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res 17(3):303-340
18. Li Z, Meredith MP. 2003. Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics. J Biopharm Stat 13(4):777-792 (Pubitemid 37259717)
19. Lin DY, Zeng D. 2010. On the relative efficiency of using summary statistics versus individual-level data in meta-analysis. Biometrika 97(2):321-332
20. Neaton JD, Wentworth D. 1992. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152(1):56-64
21. Prentice RL. 1989. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8(4):431-440 (Pubitemid 19105891)
22. Rasnake CM, Trumbo PR, Heinonen TM. 2008. Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease. Nutr Rev 66(2):76-81 (Pubitemid 351666652)
23. Robins JM, Greenland S. 1992. Identifiability and exchangeability for direct and indirect effects. Epidemiology 3(2):143-155
24. Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A. 2009. Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 22(2):244-261
25. Stallard N. 2010. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information. Stat Med [Epub ahead of print].
26. Stallard N, Todd S. 2010. Seamless phase II/III designs. Stat Methods Med Res [Epub ahead of print].
27. Sutton AJ, Higgins JP. 2008. Recent developments in meta-analysis. Stat Med 27(5):625-650 (Pubitemid 351278810)
28. Thompson SG, Higgins JP. 2002. How should meta-regression analyses be undertaken and interpreted? Stat Med 21(11): 1559-1573. 1999. (Pubitemid 34746063)
29. Scientific concepts of functional foods in Europe: Consensus document. Br J Nutr 81(Suppl 1):S1-27.